The Boehringer Academy (www.boehringer-academy.co.uk) contains hundreds of hours of CPD material on equine, companion and production animals. It comprises a mixture of webinars, podcasts, short videos and downloadable documents, which can be viewed at any time. The site keeps a CPD log for each user and provides downloadable certificates.
Boehringer’s Small Animal Marketing Team Leader, Jemima Mead said: "We already have just over 15,000 vets and nurses in the UK and Ireland currently registered with the Academy.
"New and existing members are eligible to receive the Boehringer Academy colouring book. They simply have to visit www.boehringer-academy.co.uk and complete their profile. In addition, everyone completing their profile will be entered into a draw to win an iPad Pro and Apple Pencil."
DG Sanco, the EU Directorate General for Health and Consumers, has launched a worldwide photo competition to mark World Vet Year: 'Vets in your daily life'
Entries need to be photos of a vet (or vets) at work or in any situation which shows the diverse nature of the job. Five winners will win 1000 Euros worth of photographic equipment. The overall winner will win an additional 2000 Euros worth of photographic equipment. All winners will also be given travel and accommodation for the awards ceremonies in Paris and Brussels.
Anyone (except for employees of the European Institutions, and their families) can enter the competition, which closes on 31st March 2011. More details can be found at: www.vetsinyourdailylife.org.
Here's the promotional video for the competition:
Maprelin, which contains a new active molecule, Peforelin, is a gonadotropin releasing hormone (GnRH). A single, low volume injection of the ready-to-use solution induces oestrus in sows after weaning, and in sexually mature gilts where oestrus has been synchronised with Regumate Porcine.
According to the company, it works by selectively inducing the release of the animal's own follicle stimulating hormone (FSH), leading to follicle growth - critical to successful reproduction - and the stimulation of oestrus. Conventional GnRHs, because of their mode of action, are used mainly to induce ovulation.
Janssen says Maprelin is the next step in its pig reproduction programme, named Syncoris. Cornerstone of this programme is Regumate for gilt synchronisation.
Trials have shown that with the use of Maprelin (compared with control groups of breeding animals) the number of gilts and sows showing oestrus within six days of treatment increased by about 15 percentage points (Table 1). For first-litter sows the figure was more than 8 percentage points. The duration of oestrus was not affected.
Gilts came on heat two days faster than with Regumate alone, and the weaning to oestrus interval with sows achieved similar statistically significant reductions.
Farrowing rate increased by over 5 per cent for sows, by 6 per cent for first-litter sows and just on 8 per cent for gilts.
Added to those benefits, for each 100 inseminations sows produced an extra 104 piglets, first-litter sows 105 and gilts an even more impressive 158. All gilt groups in the trials, including the control groups, were synchronised with Regumate. With unsynchronised gilts it is not possible to predict the correct time to inject Maprelin.
Phil Macdonald, the company's UK pig and poultry business manager, says the objective of every producer is profitable pigmeat production. "In the UK and other EU states the costs of feed, housing and labour are considerably higher than in other major pig-producing sectors of the world.
"This makes it important for UK producers to optimise management of the reproductive process. Maprelin is a valuable tool that can help with this objective."
The precision injection gun with Maprelin enables accurate delivery of the small amounts required. Gilts require a 2.0 ml dose 48 hours after their last Regumate treatment, first-litter sows a 0.5 ml dose 24 hours after weaning and multi-litter sows 2.0 ml 24 hours after weaning. Injections are intramuscular.
The solution requires no mixing, reducing the possibility for errors. Opened vials have a shelf life of 28 days and unopened vials a shelf life of two years. Sows and gilts need only one injection per parity, and the withdrawal period for meat and offal is zero days.
The disease had been identified as a priority by the Wales Animal Health and Welfare Framework Group.
Further details will be announced in the coming months following ongoing discussions with industry representatives.
The Minister said: "Sheep scab has significant economic consequences for sheep producers and animal welfare issues for sheep. It is one of the most contagious disease of sheep in Wales and eradicating it is a priority for us and the industry.
"I’m pleased to be able to announce £5m Rural Development Programme funding will be used to help support the industry tackle the disease. Eradicating the disease has the potential to deliver significant lasting economic benefits for the sector at a particularly challenging time as we prepare to leave the European Union."
Ceva Animal Health has announced two additional dates and locations for its ‘Building Success Around the Fertility Routine Visit’ CPD days for young vets.
Part of Ceva’s reprodAction programme, the courses are intended for recent graduates, or those new to dairy practice.
The two upcoming meetings, listed on VetSurgeon.org's new RSVP-enabled CPD & Events Diary, are to be held at The Best Western Dryfesdale Hotel in Lockerbie, Dumfries and Galloway on 22nd September and the West Lancashire Investment Centre in Skelmersdale, Lancashire on 23rd September.
The company says that the courses adopt a novel ‘physiology first’, practical approach to managing cattle reproduction, and have been set up to support vets in performing routine fertility visits. They cover various topics including: identifying clients’ goals, setting herd targets and increasing pregnancy rates.
Katherine Timms, Veterinary Advisor at Ceva, said: “We have had such positive feedback from the previous events, it has encouraged us to organise more, giving vets from other areas in the UK an opportunity to attend”.
“Routine fertility visits often intimidate recent graduates, as they are normally performed solo, with little or no support. This can make it hard for vets to build confidence, which this course addresses by not only providing knowledge but also by vets who are at the same stage in their careers to interact and share experiences.”
An attendee of the course held in April, Amy Cox from Nantwich Farm Vets, spoke about her highlights of the event, saying: “It really gave me the confidence in my own knowledge of cow reproduction and helped me build on what I’d already got.
“The lecturers were really engaging and the content was highly interactive which I feel helps you learn more. This is the second reprodAction CPD course that I’ve been on so I would recommend them”.
Paddy Gordon, Director of Shepton Veterinary Group, is one of the leaders of the event. He said: “Cattle reproduction CPD can be complex and is usually theory based; these events aim to cover the basics and most importantly, how to implement it all practically. This includes how to communicate concepts to farmers, through group discussion and role play and how to implement treatment protocols practically.”
Vets who are interested in attending either of the upcoming reprodAction Young Vet Initiative CPD courses can apply via Ceva Territory Managers, Bryan Hamilton on 07753 447226 or bryan.hamilton@ceva.com for the Lockerbie meeting and Kimberly Campbell on 07831 359128 or kimberly.campbell@ceva.com for the Skelmersdale meeting.
And if you're going, don't forget to use the RSVP facility on VetSurgeon.org to let other members know you'll be there.
Pfizer Animal Health has launched Poulvac, the first modified live vaccine against E.coli in chickens.
The company claims that the vaccine, which can be used from one day of age, is set to bring major benefits in safeguarding the health of broilers, pullets for egg laying and breeding stock.
According to Pfizer, E.coli is one of the most significant bacterial pathogens found in chicks during the first week, leading to problems throughout the life of a flock including inferior performance, lack of uniformity and increased mortality. It is a costly, widespread problem for the UK poultry industry.
The vaccine was developed from research beginning in the 1990s at the Government's veterinary laboratories at Weybridge (now AHVLA) in the UK, employing genome technology to produce an avirulent strain of E.coli that induces protective immunity to the pathogenic strains of the bacteria.
The vaccine is completely non-pathogenic, and does not persist in the bird or the environment for any significant period of time. A gene deletion in its development restricts in vivo replication and leaves behind activated macrophages ready to respond to pathogenic E.coli strains.
Dr Stuart Andrews, poultry technical manager of Pfizer in the UK and Ireland said: "Poulvac E. coli provides broad cross protection against the key serotypes of E. coli infecting chickens. It is the only modified live, nonreactive vaccine proven to meet the European regulatory requirements for efficacy and safety.
"Trials have confirmed that Poulvac E.coli does not persist in the bird and proves to be self-limiting. The vaccine can survive in the environment for only a short time, and spread to in-contact birds is also limited."
The vaccine is administered as a coarse spray with onset of immunity 14 days afterwards and duration of immunity for up to 12 weeks. It can be used from day-old up to six weeks before the onset of lay, and has a nil day withdrawal period.
In the USA where Poulvac E coli has been available for six years field experience has shown the considerable benefits. In the Midwest where average layer mortality at 50 weeks of age was 2.31 per cent, this was reduced to 1.51 per cent with three doses of the vaccine*. In Eastern USA flock mortality compared with five previous flocks was reduced from over three per cent to one per cent.
A field trial in the USA with more than 300,000 broiler breeders vaccination before lay reduced mortality from 2.8 to 1.9 per cent - with only two out of 28 flocks needing antibiotic treatment compared with 13 of the 28 unvaccinated flocks.
On a broiler field trial in Georgia over four million birds were vaccinated with Poulvac E. coli at hatch. The vaccinated birds had a better feed conversion (1.79 against 1.84 for the controls) and with condemnations at the processing plant down from 1.22 to 0.73 per cent the result was a lower production cost of 0.51¢ per lb.
In another broiler trial covering more than two million birds in Arkansas livability was improved from 95.20 to 95.77 per cent and feed conversion improved from 1.95 to 1.90, gaining 0.45¢ per lb.
* Pfizer says it is important to note that in these studies carried out in the USA more than one dose of the vaccine was often administered. A single vaccination is licensed in the Summary of Product Characteristics however, where clinical disease requires and at the discretion of a veterinary surgeon, the vaccination schedule may be re-started as there is no contra-indication on the SPC.
With dysentery apparently at its highest level for many years, Pfizer Animal Health has launched a new campaign to help increase awareness of the benefits of selecting the best prevention and treatment options.
Nigel Lodge MRCVS, Pfizer technical manager said: "The increase in dysentery can be attributed to a combination of factors including more frequent movement of weaners and a reduction in the level of feed medication resulting from the increasing use of more vaccines against other disease.
"With the early onset of winter, we know that dysentery will survive outside the pig for up to seven weeks in cold moist conditions and other pathogens for considerably longer."
The campaign is headed by a new guide, 'Enteric Disease Management', which looks at prevention and treatment of the problem, one of the most costly to the producer. Dysentery alone is estimated to cost more than £10 / pig finished considering higher mortality, increased feed costs and non-marketable animals.
The guide says that according to the housing system some of the pathogens have extremely long survival times - three months for E coli, nine months for salmonella and one year for coronavirus (transmissible gastroenteritis). It provides advice on limiting infection and reducing stress on the pigs.
Mr Lodge says that the incidence of dysentery fluctuates in different areas of the country with varying antibiotic sensitivity. Hence, a sensitivity test is essential when deciding on a particular medication.
With enteric diseases in general, there are a wide range of causes - including bacteria, viruses, parasites, management or nutrition. Mr Lodge said: "The causal agent can sometimes be diagnosed from clinical signs, such as dysentery, but generally post mortem and laboratory diagnosis is required.
"There are various antibiotic products which can be used but all should only be used after management issues such as bio security, pen management and rodent control have been addressed.
"Some products are specific in their activity, such as Lincocin Premix and swine dysentery. Others have a broad spectrum of activity and should be used where mixed infections are diagnosed. Linco-Spectin Premix, for instance, is active against E coli, Salmonella, ileitis, swine dysentery and other enteric bacteria."
Copies of the new publication - including a competition to win two prizes of one tonne of pig feed - are available from Pfizer Animal Health via Scott Wheway Tel: 01737 330941 or scott.a.wheway@pfizer.com
The company has published data from its 2021 Assure Ewe subsidised testing scheme, which found that 48% of farms that submitted samples after last year’s lambing season tested positive for EAE1 caused by Chlamydia abortus.
This, Ceva says, mirrors the results from the 2020 testing initiative, demonstrating that EAE remains a significant issue on UK farms.
Katherine Timms BVetMed (Hons) MRCVS, ruminant veterinary advisor at Ceva Animal Health said: “EAE is a significant problem on UK farms, and it can be exceptionally expensive and frustrating to deal with, as infected sheep aborting and shedding have the potential to cause an abortion storm the following year.
“Any abortion outbreak should therefore be identified and managed as quickly and effectively as possible to help prevent the rest of the ewes in the flock from becoming infected.
"Vaccination and strict biosecurity provide the best protection against EAE and farmers can vaccinate their ewes from five months of age until four weeks prior to tupping, as long as the ewe is not in lamb.”
For further information, contact your local Ceva Animal Health account manager or visit www.enzooticabortion.co.uk.
Reference
MSD Animal Health has launched Bovilis IBR Marker Inac, an inactivated marker vaccine for use in the control of Infectious Bovine Rhinotracheitis (IBR).
The company says the new product complements Bovilis IBR Marker Live and creates a range now offering greater simplicity and additional flexibility for veterinary surgeons seeking optimum control protocols for their clients' herds.
MSD Animal Health ruminant veterinary adviser Drew McGurren MRCVS said: "Farmer compliance is an important part of any successful vaccination programme. With this extended Bovilis IBR Marker programme, farmers can now start IBR vaccination of their cattle from three months of age with a single shot primary course of Bovilis IBR Marker Live, easily followed by boosters every six months using a single dose of either Bovilis IBR Marker Live or Bovilis IBR Marker Inac. Both primary course and boosters can be administered by the same intramuscular route.
"Alternatively, Bovilis IBR Marker Inac can be administered to cattle from three months of age as a primary course of two injections four weeks apart. The programme then follows a six monthly single dose booster regime.
"The availability of Bovilis IBR Marker Inac provides a simple control option in defined farm situations, not least where an alternative to the live vaccine is preferred or required. Overall, we see this development adding convenience, ease of use and flexibility for veterinary surgeons as they work with their clients to control a significant disease threat in dairy and beef cattle in the UK."
Bovilis IBR Marker Inac is a prescription-only medicine (POM-V). The product is available from wholesalers now in 10 and 50 dose vials. For further information, contact the MSD Animal Health Veterinary Support Group on 01908 685685.
Andrea Tarr BPharm MSC MRPharmS, the founder and director of Veterinary Prescriber said: "Prescribing is a neglected aspect of veterinary practice. When it comes to making treatment decisions, vets are very poorly supported by their professional organisations, the pharmaceutical industry has a hugely distorting influence and there's a lack of access to really helpful information.
"We're determined to use the expertise in Veterinary Prescriber to change this, and support vets in their use of medicines in the best interests of animals, their owners and the environment.
"With this in mind, we start the year with a learning module of good veterinary dispensing practice."
The module explains what constitutes a well-run dispensary, including how to organise, handle and store medicines correctly. It reviews the legal classifications of medicines, including controlled drugs and the cascade. It also considers why dispensing errors occur and what to do when they happen.
Veterinary Prescriber says its modules are evidence-based, peer-reviewed and independent of the pharmaceutical industry.
Subscription costs £9.95 per month, which you can cancel any time. To subscribe, visit: www.veterinaryprescriber.org
BCF Technology has launched the Sonosite Edge ultrasound system.
According to the company, the new system is suitable for both small animal and equine reproduction, abdominal, musculoskeletal, cardiac and ophthalmic applications.
The Sonosite Edge was apparently designed for use in battlefields and disaster zones, so it should withstand veterinary use. It is upgradeable to Colour, Pulsed Wave (PW) and Continuous Wave (CW) Doppler. It can also be DICOM enabled. It weighs 15kg and has a start up time of less than 15 seconds. There is a range of linear, mico-convex, convex and phased array probes available.
The system with one probe starts around £22,000.
Nigel Perry, BCF Account Manager said: "The Sonosite Edge offers an excellent system with superior image quality than has not been seen on a field-based system before. This is a perfect system for a mixed practice looking to perform a wide range of applications. It is very durable and can be taken anywhere."
To find out more about the Sonosite Edge, visit www.bcftechnology.co.uk or call +44(0)1506 460 023.
Free-range table-birds being reared from slower growing breeds need a different vaccination regime from that of faster-growing broilers, when being immunised against Gumboro disease.
This previously-unknown fact has emerged from laboratory and field trials, involving several hundred thousand birds on farms throughout the UK, carried out by Lohmann Animal Health in conjunction with poultry vets.
"When using a ‘hot' vaccine conventional broilers in the UK are normally vaccinated at around 14-16 days when their maternal immunity is waning," said Adam Goddard, Lohmann's UK sales consult. "However, we've found this maternal immunity lasts longer in the slow-growing breeds which are reared both indoors and out."
Realistically, the correct day of vaccination for free-range table-birds is more likely to be achieved by using the vaccine date predictions for broiler-breeders, rather than that of the broiler, under the Deventer formula, which gives calculations for different types of bird.
He therefore advises producers to consult their vets who can take blood samples to get an accurate prediction regarding optimum timing of vaccination with their own particular flocks.
"Our trials have shown that, in general, and depending upon the breed used, the decline in maternal immunity is delayed - perhaps for 4-5 days. So, in order to get a better ‘take', we recommend vaccinating these birds later or using an IBD vaccine that ‘takes' in the presence of high maternal immunity." said Mr Goddard.
Gumboro disease - also known as Infectious Bursal Disease - can cause severe losses in chickens and outdoor-reared birds are more susceptible to the disease due to environmental influences.
Earlier this year Lohmann Animal Health launched a new ‘hot' vaccine, classified as an ‘intermediate plus' against the very virulent form of Gumboro disease. The company says that because of its ability to break through high levels of maternal antibodies, it allows vaccination to take place earlier than with other existing vaccines.
London's Savile Row was turned into a sheep field today, to highlight The Campaign For Wool; a coalition of industry groups convened by HRH The Prince of Wales to educate consumers about the benefits of wool.
As the sheep grazed, the Row's famous tailoring houses held events where the public could find out more about the natural, sustainable qualities of wool.
Douglas Cordeaux, Managing Director of West Country woollen mill Fox Brothers, one of the organisations behind the promotion said: "We have a collective responsibility to champion this versatile, sustainable and natural fibre, the production of which involves far lower carbon emissions than man‐made alternatives. We need to support farmers who are the custodians of our rural landscape and truly value the qualities of this wonderful resource, which is used to weave the finest luxury cloth you can buy."
John Thorley of the Campaign for Wool said: 'I'd like to see wool re-established as a fibre of consequence where workers get paid properly and people recognise that this animal is useful to the farming sector in a multitude of ways.'
For more information, see www.campaignforwool.org and www.savilerowfieldday.com
Fort Dodge, which supplies Bluetongue vaccine in continental Europe, has licensed its cattle vaccine in the UK and is now launching the product onto the UK market.
The company has already won and met tenders from several European governments, including France, Spain, Italy, Portugal Germany, Switzerland, Belgium and the Czech Republic for its Zulvac 8® Bovis vaccine and says it is the only international company to have produced vaccines for the most commonly occurring serotypes of the disease including 8, 4 and 1.
Approved by the VMD with a Provisional Marketing Authorisation, Zulvac 8 is available in 50 dose and 10 dose packs. The key claims are active immunisation against Bluetongue serotype 8 of cattle from 2.5 months old and a significant reduction of viraemia.
The vaccine is administered in 2 x 2 ml doses at three week intervals given by intra muscular injection and the product is supported by a fixed 2ml multidose applicator with Sterimatic needle protector and cleaning system to ensure accurate dosing and hygienic conditions.
John Hanley, Managing Director of Fort Dodge UK, said: "We were first to market with our Zulvac 8 product in three European countries and have received an Award for Agricultural Merit from the Spanish Government for our work in Bluetongue control. Following the licensing of Zulvac 8 Bovis in the UK we now have the opportunity to launch the product onto the UK market.
"In terms of pricing, Zulvac 8 is competitive per dose against other products in the market and it is supported by the experience gained in Europe with millions of animals already vaccinated. We're delighted that the VMD have authorised the vaccine and believe its availability can play a key role in protecting the UK's cattle from this dreadful disease."
The product is authorised for use by cattle farmers in the protection zone only, and will require veterinary prescription. Farmers can administer the vaccine to their cattle and the 2ml intra-muscular injection will be an advantage in aiding administration especially when used with Zulvac Bovis applicator with sterimatic needle protector and cleaning system.
The first batches will be available from veterinary wholesalers from week commencing 22nd September 2008.
Bovilis Rotavec Corona is used for the active immunisation of pregnant cows and heifers, 12-3 weeks pre-calving, to raise antibodies against rotavirus, coronavirus and E. coli F5 (K99). Calves gain protection by drinking the fortified colostrum from their vaccinated mothers.
The company says the new license indication will mean greater usage flexibility for UK cattle producers focusing on immunity-led prevention of infectious calf scours.
MSD ruminant veterinary adviser Dr Kat Baxter-Smith said: "On the old license, this vaccine needed to be used within eight hours of opening, so this will be a significant benefit-led change for suckler beef and dairy producers.
"For all-year-round calving dairy herds, for example – that may want to vaccinate successive pregnant dams on different days – it will make an opened bottle of vaccine last much longer. Those running batch calving herds with a long calving period should also benefit. We hope this will help reduce unnecessary wastage of the vaccine on farm and save farmers money.”
MSD says it will still be crucial to store the vaccine properly – upright and refrigerated (at 2-8°C) before and after broaching, and after first use. A broached vial will be able to be used once more during the next 28 days after the first vaccination event and then discarded. Vaccination equipment such as needles and syringes should be sterilized. Use of a multi-dose syringe to minimise vaccine contamination and excessive broaching is recommended.
The vaccine vials should still be shaken well before use. The injection should be made through an area of clean, dry skin with precautions taken against contamination.
This, says the government, would be one of the toughest sanctions in Europe, strengthening the country's claim to be a global leader on animal welfare.
The Animal Welfare (Sentencing) Bill comes after a public consultation held last year which found that more than 70% of people supported proposals for tougher prison sentences. It will allow the courts to take a tougher stance on things like dog fighting, puppy and kitten abuse, and neglect of farm animals.
The new Bill has been welcomed by animal welfare charities.
Chief Executive for the RSPCA, Chris Sherwood, said: "This reform is long overdue. Those responsible for extreme cruelty towards animals or those criminal gangs involved in organised animal crime will now face the tough justice they deserve.
"We need to better protect our animals and the RSPCA hopes that this new Animal Welfare (Sentencing) Bill will give courts the powers they need to punish those responsible for the most unimaginable cruelty to animals.
"We also believe this will act as a much stronger deterrent to others and help us stamp out animal cruelty once and for all."
James Yeates, Cats Protection’s Chief Executive said: "We very much welcome this announcement which is an important step in ensuring the UK is one of the world leaders on animal welfare issues.
Claire Horton, Chief Executive of Battersea Dogs & Cats Home, said: "The introduction of this bill is a landmark achievement, which will make a profound difference to dogs and cats in England and Wales."
Suvaxyn PRRS MLV offers the earliest piglet vaccination from the first day of age, securing immunity before the risk period which lasts until the end of the fattening. Pig protection is established 28 days after vaccination, and lasts for 26 weeks after vaccination in fattening pigs, and 16 weeks after vaccination in gilts and sows. Zoetis says the vaccine reduces viremia and nasal shedding of the virus.
Monica Balasch, Associate Director, Global Biologicals Development at Zoetis said: "In Europe, Porcine Reproductive and Respiratory Syndrome is known for severe impacts on reproduction including lowering birth rates, increasing abortion, stillbirth, mummified, as well as weak live-born piglets, and death.
"In clinical studies conducted with Suvaxyn PRRS MLV, we found excellent results vaccinating pigs from the first day of age. It is safe to be used as the earliest protection in piglets, and to protect the whole herd against PRRS, as it is also safe for use in gilts and sows.
"The new vaccine represents a flexible alternative to allow for new customized PRRS control programs developed by veterinarians for producers."
Alvaro Aldaz, Director, Commercial Development and Innovation, Swine, at Zoetis said: "We are excited to bring this innovative vaccine to Europe. Suvaxyn PRRS MLV has been developed using a very innovative vaccine technology which brings swine veterinarians a new advanced PRRS control tool.
"As well reducing viremia, nasal shedding and lung lesions in fattening pigs, the vaccine has been proven to overcome maternal immunity, which increases the efficacy of the vaccine when given to piglets during the first days of life. Additionally, it allows veterinarians for use PRRS mass vaccination within the claim; mass vaccination has become more and more popular in several European countries."
Suvaxyn PRRS MLV is a veterinary vaccine that contains a European PRRS virus strain (Genotype 1) that has been grown and attenuated in a uniquely modified cell line developed by Zoetis.
Jay Calvert, Research Director, VMRD Global Biologicals Research at Zoetis said: "Suvaxyn PRRS MLV is safe based on true loss of virulence, and not based on a temporary reduction in ability to replicate in macrophage cells in the lung of the pig."
Zoetis says the efficacy of Suvaxyn PRRS MLV is supported by a comprehensive program of clinical studies reviewed by the European Medicines Agency and included in the regulatory procedure approved by the European Commission in August 2017.
The European public assessment report is available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/veterinary/004276/WC500235212.pdf
The company says the most common side effects with Suvaxyn PRRS MLV (which may affect more than one in 10 pigs) are a short-lived increase in body temperature (0.5°C on average and up to 1.4°C individually) within four days of vaccination, and in sows local reactions in the form of swellings which resolve without treatment within five to 32 days.
Initial laboratory tests on the samples taken this morning from the cattle on the holding in Surrey where disease was suspected have indicated the presence of Foot and Mouth Disease. On the basis of these initial laboratory results and clinical symptoms Debby Reynolds, UK Chief Veterinary Officer (CVO), has confirmed Foot and Mouth Disease. The farm comprises a number of separate parcels of land and a single Protection Zone will be put in place which extends a 3 kilometres radius from each of them, and a Surveillance Zone of 10 kilometres radius beyond that. Footpaths will be closed in the Protection Zone.
Horiba says subclinical hypocalcaemia (SCH) is a significant and under-diagnosed metabolic problem in dairy cattle affecting up to 50% cows annually.
After lactation, total calcium levels in the cows’ blood drop which can lead to sub-optimal health and yield.
The webinar will be presented by James Husband BA, VetMB, DipECBHM, DCHP, MRCVS, who will offer the benefit of his research and experience on the subject.
At the end, there'll be a Q&A session.
During the webinar, Horiba will also introduce its patient-sideLAQUAtwin Ca-11C pocket meter, which measures blood ionised calcium levels fast and is currently on special offer until 30th June 2022.
To register, visit: https://register.gotowebinar.com/register/6274625209458361872
Norbrook has announced the launch of Spotinor Deltamethrin spot-on, a new product which kills a wide range of external parasites that can have economically damaging effects on cattle, sheep and lambs.
The product is effective against lice and flies on cattle, ticks, lice, keds and established blowfly strike on sheep, and lice and ticks on lambs. It is available in 250ml and 500ml squeeze neck dispensing packs as well as a 1 litre and 2.5 litre backpack with dosing gun. The dose is 10ml for cattle, 5ml for sheep and 2.5ml for lambs (under 10kg/1 month of age).
Spotinor has a zero milk withhold time.
Edward Haughey, Director of Norbrook GB, said: "As Britain's leading veterinary pharmaceutical company, Norbrook is committed to providing British farmers and vets with the products and services they need to manage animal health effectively. Spotinor is the first generic to market, which displays the same benefits as the pioneer product. We are delighted to launch Spotinor, which gives livestock producers a greater choice of safe and sound solutions for the control of external parasites."
For more information, contact your Norbrook representative, telephone +44 (0) 1536 741 147 or email: enquiries@norbrook.co.uk
The survey for vets is about two minutes long: www.smartsurvey.co.uk/s/ZCONJA/.
A prize draw will be carried out after the survey closes with 10 participants winning a Q fever snood.
Renzo Di Florio, veterinary advisor at Ceva Animal Health, said: “Despite Q fever being endemic in GB dairy herds1, we believe that awareness amongst farmers and the related farming industries is low.
"Our national Q fever surveys will help us ascertain how we can support farmers and vets when it comes to diagnostic challenges, treatment options and prevention through vaccination to help protect farmers, farming families and the related professions from the disease and reduce the impact of Q fever on farms.”
Jonathan Statham MA VetMB DCHP FRCVS, a RCVS registered specialist in cattle health, co-author of the ‘Dairy Herd Health’ textbook and chief executive of RAFT Solutions, added: “Multiple surveys in the UK support Q fever prevalence ranging from 60 to 80% in our national dairy herd, including recent work carried out by RAFT Solutions in NE England and SW England (2021)2.
"Reproductive issues are of course multifactorial and it is important therefore not to associate a Q fever positive diagnostic result as a single cause of infertility.
"However, increased level of metritis and endometritis, abortion and pregnancy loss or extended calving-conception intervals merit further investigation with Q fever as part of a herd health discussion that should of course address other infectious disease such as BVD, IBR or leptospirosis.
"Q fever is of further significance as a zoonosis and also as a potentially emerging disease in the context of climate change and changing vector patterns.”
Ceva has also launched a social media toolkit containing social media graphics and content on the disease that can be posted on vet practice social media channels, available from your local Ceva account manager.
References
Lucy Chadwick, Head of Technical Services & Marketing at Forte Healthcare Ltd said: “Neonatal calf diarrhoea is a leading cause of death in the calf crop in the UK and Ireland.
"We are delighted to therefore offer this webinar discussing up to date information on what we can do to boost neonatal defences in the face of an NCD outbreak.
"Tune in to learn more about the importance of colostral antibodies and how the resecretion of antibodies plays a key role in gut protection.
"We will also discuss what factors can influence the effectiveness of a NCD vaccination programme and what this means for your farmers.”
You'll be able to ask questions during the event and the webinar will also be made available to watch on demand afterwards.
https://www.thewebinarvet.com/pages/forte-healthcare-register
Ms Padron Vega had also been found to have failed in her duties as an OV by being unprepared for, and unaware of, new regulations. She also did not take adequate steps to ensure that the two individuals for whom she had given veterinary certification were licensed to perform slaughter in accordance with the regulations.
Ms Padron Vega originally applied for restoration in December last year, at which time the Disciplinary Committee had concerns about her keeping up-to-date with the knowledge and skills needed to return to practice, and decided to adjourn for six months to allow her to prove that it was appropriate to restore her name to the Register.
At the latest hearing, Ms Padron Vega sought to address the concerns that the Committee had raised about her professional development. In addition to the documentation she provided in her original restoration hearing, which included positive testimonials from colleagues, she provided evidence of her continuing professional development (CPD).
This included a letter from her previous employer, who confirmed she had more recently worked for them as a Certification Support Officer from February to March 2021, where they received positive feedback on her conduct.
The documentation also included a letter from another practice confirming that Ms Padron Vega had been offered a position of employment with them, and a separate letter from practice veterinary surgeon, Dr Khan MRCVS, confirming that he would be her mentor. Dr Khan also confirmed that she had been coming to the practice for work experience and he considered her to have good working knowledge of current medicines used within the practice. He further outlined in his letter what CPD support the practice would be providing for Ms Padron Vega as part of her employment with them.
An additional piece of evidence was a testimonial from Dr Max Rutana MRCVS who confirmed that Ms Padron Vega had worked unsupervised for a period of three weeks, and that he found her clinical notes during this period to be satisfactory and they received no complaints about her conduct from clients.
Ms Padron Vega also submitted CPD documentation which confirmed she has taken a Certification Support Officers’ course and examination in mid-December 2020.
In response to questions from the Committee about her small animal practice experience and how long she had been shadowing Dr Khan for, Ms Padron Vega explained that she had completed 80 hours of shadowing with Dr Khan and that in her future employment under his mentorship, he would be available to support her. She also explained that her job offer was evidence that she would continue to be trained in the relevant area of veterinary work.
Cerys Jones, chairing the Disciplinary Committee and speaking on its behalf, said: “During the hearing, we heard evidence from Dr Khan who provided reassurance of Ms Padron Vega’s continued professional development with his practice and the ongoing supervision that she would be under. He explained that the supervision would last at least three months.
“The Committee’s view is that Ms Padron Vega accepts the findings of dishonesty that were made against her at the original Inquiry hearing. In her Reflective Statement, she acknowledges that veterinarians have a professional responsibility to ensure the integrity of veterinary certification, that she is now aware that when signing documents as a veterinary surgeon they need to be approached with care and accuracy. Further she has undertaken a CPD course on this very ethical issue and has passed the examination set at the end of that course. The Committee is confident that Ms Padron Vega is unlikely to repeat the conduct which resulted in her being removed from the Register. It is the Committee’s decision that she should be restored to the Register.”
Vetoquinol has announced the introduction of Melovem to the UK market. Melovem is a new injectable preparation containing 5mg/ml meloxicam which is licensed for use in pigs and young cattle.
According to the company, meloxicam is the most widely used veterinary non steroidal anti-inflammatory injection in the UK. Presented in 100ml bottles, with a lower dose formulation, Melovem can be a cost-effective NSAID solution to leave on-farm.
Mark Leddy from Vetoquinol said: "We are pleased to be the distributors of Melovem in the UK. Melovem provides vets and farmers with a new, cost-effective meloxicam injection that is suitable for on-farm use."
Contact your Vetoquinol representative for more information on Melovem, or call Vetoquinol on 0800 1608197.
The RCVS has brought out a new publication to help members of the veterinary and veterinary nursing professions understand their legal and professional obligations regarding controlled drugs.
Controlled Drugs Guidance is a consolidation of existing advice and guidance on controlled drugs from a number of organisations including the RCVS itself, the Veterinary Medicines Directorate (VMD), the British Small Animal Veterinary Association (BSAVA) and the Home Office. The guide also gives details of the existing legislation concerning controlled drugs, namely the Misuse of Drugs Act and associated regulations.
The guidance provides advice on a variety of topics to reflect the common queries the RCVS Advice Team receives, such as storage, destruction and disposal; keys and keyholders for controlled drugs cabinets; controlled drugs in vehicles; and veterinary nurses administering controlled drugs.
The publication also deals with specific controlled drugs such as ketamine which, on 30 November 2015, was rescheduled to a Schedule 2 controlled drug, meaning that it is now subject to the same strict storage, prescription, dispending, destruction and record-keeping requirements as other medicines in this Schedule.
Laura McClintock, Standards and Advisory Manager at the RCVS, said: “We hope that this publication will help members of the profession navigate the often complex legislative and professional requirements regarding controlled drugs, as well as imparting best practice advice on how they should be stored and disposed and so on.
"This publication has also been endorsed by our colleagues in the Home Office, VMD and BSAVA and, because this is an area that is subject to regular change, we will make sure to keep it up-to-date as and when the regulations change."
The publication is available to download from the RCVS website at www.rcvs.org.uk/publications